Abstract
Pharmaceutical firms are making progress in addressing the need for new antifungal therapies. F2G, which specializes in the treatment of rare fungal diseases, says it will receive $100 million from the Japanese firm Shionogi in a deal to develop olorofim, an antifungal agent for invasive aspergillosis and other rare mold infections. This news follows Mycovia Pharmaceuticals’ statement April 28 that the US Food and Drug Administration approved its azole antifungal Vivjoa (oteseconazole) for chronic yeast infections. The announcements reflect efforts to fill gaps in treating fungal infections, which have limited treatment options and increasing resistance . Olorofim is part of the first new class of antifungals to be developed in 20 years, according to F2G. Chief Operating Officer Mike Birch says the firm is preparing a new drug application to submit to the FDA later this year. The deal with Shionogi is focused on Europe and Asia. Olorofim works by
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
